Development of multi-epitope peptide-based vaccines against SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic involving so far more than 22 million infections and 776,157 deaths. Effective vaccines are urgently needed to prevent SARS-CoV-2 infections. No have yet been approved for licensure by regulatory agencies. Even though host immune responses beginning be unravelled, effective clearance of virus will depend on both humoral cellular immunity. Additionally, the presence Spike (S)-glycoprotein reactive CD4+ T-cells in majority convalescent patients is consistent with its significant role stimulating B CD8+ T-cells. The search immunodominant epitopes relies experimental evaluation peptides representing from overlapping peptide libraries which can costly labor-intensive. Recent advancements B- T-cell epitope predictions bioinformatic analysis led identifications. Assessing induce potent neutralizing antibodies robust prerequisite selection incorporated peptide-based vaccines. This review discusses roles validations B-, could lead construction multi-epitope vaccine. Peptide-based known their low immunogenicity overcome incorporating immunostimulatory adjuvants nanoparticles such as Poly Lactic-co-Glycolic Acid (PLGA) or chitosan.